• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Run from Galderma Rx

Quote








Politic queen AL is driving the other company she joined into the ground..heard from some folks she is already hated by most people at the company…tanking stock price doesn’t help. Hiring “yes” people is not the recipe for success AL. Stop politicking and start doing the right thing.
 




anonymous said:
Politic queen AL is driving the other company she joined into the ground..heard from some folks she is already hated by most people at the company…tanking stock price doesn’t help. Hiring “yes” people is not the recipe for success AL. Stop politicking and start doing the right thing.
Click to expand...
AL the tied is gone but she has left her shitpile leadership team behind like skidmarks. Have to deal with these assholes everyday
 












Can we at least see what this team does first with the new drug before commenting that it will be sold or that this division sucks. Derms love Galderma but yes they have some questions since they have never been in the biologics space before. I think there are a few people in the RSM ranks that have the experience so hopefully the company leans on those individuals to help pull this through. We shall see.
 












Juuuuiio
anonymous said:
Can we at least see what this team does first with the new drug before commenting that it will be sold or that this division sucks. Derms love Galderma but yes they have some questions since they have never been in the biologics space before. I think there are a few people in the RSM ranks that have the experience so hopefully the company leans on those individuals to help pull this through. We shall see.
Click to expand...
tgat right there tells you the galderma mentality. You don’t get second shots in an intense market…fuck up once and you’re done
 








anonymous said:
Can we at least see what this team does first with the new drug before commenting that it will be sold or that this division sucks. Derms love Galderma but yes they have some questions since they have never been in the biologics space before. I think there are a few people in the RSM ranks that have the experience so hopefully the company leans on those individuals to help pull this through. We shall see.
Click to expand...
The derm biologics space is a fierce one. If you don’t get it, you don’t get a second chance.
 




anonymous said:
If it is known then why the f are people like me busting their ass to get this out suboptimally to the market. The promise was to build out a pipeline of biologicsj. Spending this kind of money to build out a single product doesn’t make sense.
Click to expand...
Indeed that was the promise to many of us, a biologics pipeline. The challenge with Galderma is while the breadth of the business creates welcomed investment diversification, it also creates an execution nightmare. While almost all pharma companies as divesting consumer BUs, Galderma thinks is so smart to sell it under the Dermatology Integrated Strategy. Operating 3 completely different BUs requires one to make choices on which leader will lead it, and what background (Rx, Cx, Ax) they will bring along. This is a company run by Ax people (Head of US, Europe and Global) at the highest levels, you can’t expect it to be successful with Nemo…They enjoy seeing people with fake faces they aren’t in the business of patient centricity, market access, medical selling…it’s too much for them
 




anonymous said:
Indeed that was the promise to many of us, a biologics pipeline. The challenge with Galderma is while the breadth of the business creates welcomed investment diversification, it also creates an execution nightmare. While almost all pharma companies as divesting consumer BUs, Galderma thinks is so smart to sell it under the Dermatology Integrated Strategy. Operating 3 completely different BUs requires one to make choices on which leader will lead it, and what background (Rx, Cx, Ax) they will bring along. This is a company run by Ax people (Head of US, Europe and Global) at the highest levels, you can’t expect it to be successful with Nemo…They enjoy seeing people with fake faces they aren’t in the business of patient centricity, market access, medical selling…it’s too much for them
Click to expand...
well put. but isnt the team hired good? they must have Rx experience. I hear conflicting things.
 




anonymous said:
Indeed that was the promise to many of us, a biologics pipeline. The challenge with Galderma is while the breadth of the business creates welcomed investment diversification, it also creates an execution nightmare. While almost all pharma companies as divesting consumer BUs, Galderma thinks is so smart to sell it under the Dermatology Integrated Strategy. Operating 3 completely different BUs requires one to make choices on which leader will lead it, and what background (Rx, Cx, Ax) they will bring along. This is a company run by Ax people (Head of US, Europe and Global) at the highest levels, you can’t expect it to be successful with Nemo…They enjoy seeing people with fake faces they aren’t in the business of patient centricity, market access, medical selling…it’s too much for them
Click to expand...
Finally someone with common sense! When every other company is focusing, Galderma is still playing in multiple areas. Rx and Cx are the most challenging. Competing in those with limited resources and no biologic pipeline is not a winning strategy.
People with Ax background really have no idea about biologics, real world evidence, buy & bill, market access, patient advocacy, LoE…..
 




anonymous said:
Finally someone with common sense! When every other company is focusing, Galderma is still playing in multiple areas. Rx and Cx are the most challenging. Competing in those with limited resources and no biologic pipeline is not a winning strategy.
People with Ax background really have no idea about biologics, real world evidence, buy & bill, market access, patient advocacy, LoE…..
Click to expand...
Market access is set. This is not a buy and bill product. RWE doesn’t come till later by that time they would have sold. HCP advocacy more important than patient advocacy. This is a new class so why the hell would they think about LoE?
 








She has left Galderma a shit legacy. Stupid ass leaders in Rx BU making dumb ass decisions. Installed and left others with these turds. Fu*k you Aimed L wherever you are. Hope you have the worst luck wherever you went.
 




AL is the worst human on the planet. Politicking her way through life. I hope she will have regrets as she grows older with no peace of mind. I just got let go from the Nemo team - the leaders she has chosen are turds
 








Top Bottom
Back
Quote